Mizuho Maintains Outperform on Medline, Lowers Price Target to $45
Mizuho analyst Steven Valiquette maintains Medline (NASDAQ:MDLN) with a Outperform and lowers the price target from $48 to $45.
MDLN is down 1.17% today. Volume is 8.13M vs a 30-day average of 8.93M (0.91x).
Medline Inc. is scheduled to report earnings Wed, Nov 4, 2026. Analysts expect EPS of $0.36 on revenue of about $7.88B. Stocks often move sharply on earnings day.
Mizuho analyst Steven Valiquette maintains Medline (NASDAQ:MDLN) with a Outperform and lowers the price target from $48 to $45.

Medline (Nasdaq: MDLN), the largest provider of medical-surgical products and supply chain solutions serving all points of care, has announced plans to open a new distribution cen…